Imagion Biosystems Limited (IBXXF)
- Previous Close
0.0240 - Open
0.2560 - Bid --
- Ask --
- Day's Range
0.2560 - 0.2560 - 52 Week Range
0.1760 - 1.4360 - Volume
163 - Avg. Volume
0 - Market Cap (intraday)
8.358M - Beta (5Y Monthly) 1.88
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2800 - Earnings Date Aug 28, 2024 - Sep 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the MagSense nanoparticles for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.
imagionbiosystems.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: IBXXF
Performance Overview: IBXXF
Trailing total returns as of 5/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IBXXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IBXXF
Valuation Measures
Market Cap
1.60M
Enterprise Value
6.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.23
Price/Book (mrq)
--
Enterprise Value/Revenue
5.67
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-252.26%
Return on Assets (ttm)
-99.05%
Return on Equity (ttm)
--
Revenue (ttm)
5.18M
Net Income Avi to Common (ttm)
-13.07M
Diluted EPS (ttm)
-0.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
227.08k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.38M